Growth Hormone-Releasing Activity of Hexarelin in Humans (1994)
Human | 0.5-2 μg/kg IV | Single dose | 12 adult males
Double-blind, placebo-controlled dose-response study demonstrating dose-dependent GH release. Peak plasma GH at 30 minutes, returning to baseline within 240 minutes. Cmax values: 26.9 ng/ml (0.5 μg/kg), 52.3 ng/ml (1 μg/kg), 55.0 ng/ml (2 μg/kg) vs 3.9 ng/ml placebo.
View Study →
Hexarelin Treatment Preserves Myocardial Function After MI (2018)
Mouse model | 0.3 mg/kg/day SubQ | 21 days | LAD ligation
Demonstrated significant improvement in LV function after 14 days. Hexarelin treatment reduced LV collagen concentration by ~53%, decreased inflammatory cytokines (TNF-α, IL-1β), and shifted autonomic balance toward parasympathetic predominance.
View Study →
Protective Effects of Hexarelin in ALS Neuroblastoma Model (2023)
In vitro | 1 μM | Human neuroblastoma cells | SOD1-G93A mutation
Hexarelin protected cells from H2O2-induced cytotoxicity by increasing Bcl-2 expression, reducing caspase-3 activation, and modulating MAPK/Akt pathways. Significantly decreased γH2AX positive cells indicating DNA damage protection.
View Study →
Cardiovascular Action of Hexarelin Review (2014)
Review | Multiple studies | CD36 receptor mechanism
Comprehensive review establishing hexarelin's cardioprotective effects through CD36 cardiac receptor binding independent of GH release. Documented anti-apoptotic effects, reduced infarct size in ischemia-reperfusion, and improved LVEF by 6.7 percentage points in human volunteers.
View Study →
Hexarelin Desensitization Study (2000)
Human | SubQ twice daily | 16 weeks | 12 elderly subjects
Investigated long-term GH response attenuation. AUC-GH decreased significantly from baseline at weeks 4 and 16. Four weeks post-treatment, GH response recovered to baseline levels, demonstrating desensitization is partial and reversible.
View Study →
Hexarelin Pharmacokinetics in Rats (1999)
Rat model | IV and SubQ | Multiple doses | PK analysis
IV administration showed half-life of 75.9 min, clearance of 7.6 ml/min/kg, and Vd of 744 ml/kg. SubQ administration confirmed absence of accumulation with dose-independent clearance (12-15 ml/min/kg).
View Study →